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ABSTRACT
Tertiary lymphoid structures (TLS) are associated with favorable outcome in non-metastatic colorectal
carcinoma (nmCRC), but the dynamics of TLS maturation and its association with effective anti-tumor
immune surveillance in nmCRC are unclear. Here, we hypothesized that not only the number of TLS but
also their composition harbors information on recurrence risk in nmCRC. In a comprehensive molecular,
tissue, laboratory, and clinical analysis of 109 patients with stage II/III nmCRC, we assessed TLS numbers
and degree of maturation in surgical specimens by multi-parameter immunoﬂuorescence of follicular
dendritic cell (FDC) and germinal center (GC) markers. TLS formed in most tumors and were signiﬁcantly
more prevalent in highly-microsatellite-instable (MSI-H) and/or BRAF-mutant nmCRC. We could distinguish
three sequential TLS maturation stages which were characterized by increasing prevalence of FDCs and
mature B-cells: [1] Early TLS, composed of dense lymphocytic aggregates without FDCs, [2] Primary follicle-
like TLS, having FDCs but no GC reaction, and [3] Secondary follicle-like TLS, having an active GC reaction.
A simple integrated TLS immunoscore reﬂecting these parameters identiﬁed a large subgroup of nmCRC
patients with a very low risk of recurrence independently of clinical co-variables such as ECOG
performance status, age, stage, and adjuvant chemotherapy. We conclude that (1) mismatch repair and
BRAF mutation status are associated with the formation of TLS in nmCRC, (2) TLS formation in nmCRC
follows sequential maturation steps, culminating in germinal center formation, and (3) this maturation
process harbors important prognostic information on the risk of disease recurrence.
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Introduction
Colorectal Cancer (CRC) is the third most frequent malignancy
world-wide in both men and women.1 Currently, an estimated
1.4 million new colorectal cancer cases and 693,900 deaths are
annually recorded.2 Around 30–40% of patients with non-meta-
static stage II and III CRC (nmCRC) develop recurrence after
surgical removal of the primary tumor with curative intent and
these recurrences are the major determinant of CRC mortality.3
Therefore, improved prognostication of disease recurrence in
nmCRC is important in order to select patients with the highest
risk of recurrence for adjuvant chemotherapy while sparing low-
recurrence-risk patients from unnecessary and oftentimes toxic
overtreatment.4 The immune system is a critical determinant of
tumor control and disease recurrence. Several authors have
proposed that immunologic biomarkers harbor prognostic
information on recurrence risk beyond traditional parameters
such as staging.5,6 Tertiary lymphoid structures (TLS) are ectopic
lymphoid organs that develop at sites of infection or chronic
inﬂammation including cancer.7 In analogy to lymph nodes, TLS
are thought to provide important lymphocytic functional envi-
ronments for both cellular and humoral immunity.8 In autoim-
munity, TLS harboring germinal centers (GC) contribute to
disease severity by producing auto-reactive B cells and facilitating
lymphocyte inﬁltration via high endothelial venules.7 In various
cancer types, TLS correlate with improved survival including
localized and metastatic CRC,9,10 and might represent important
sites of lymphocyte recruitment into tumors as well as adaptive
immune response activation against malignant cells.6,8,11
The formation of TLS is a complex process and is orchestrated
by several lympho-organogenic chemokines in response to
CONTACT Armin Gerger, MD, MBA, Associate Professor of Medicine armin.gerger@medunigraz.at Division of Oncology, Department of Internal Medicine,
Medical University of Graz, Auenbruggerplatz 15, 8036 Graz.
yThese authors contributed equally.
Supplemental data for this article can be accessed on the publisher’s website.
© 2018 Florian Posch, Karina Silina, Sebastian Leibl, Axel M€undlein, Holger Moch, Alexander Siebenh€uner, Panagiotis Samaras, Jakob Riedl, Michael Stotz, Joanna Szkandera, Herbert St€oger, Mar-
tin Pichler, Roger Stupp, Maries van den Broek, Peter Schraml, Armin Gerger, Ulf Petrausch and Thomas Winder. Published with license by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
ONCOIMMUNOLOGY
2018, VOL. 7, NO. 2, e1378844 (13 pages)
https://doi.org/10.1080/2162402X.2017.1378844
D
ow
nl
oa
de
d 
by
 [U
ZH
 H
au
ptb
ibl
iot
he
k /
 Z
en
tra
lbi
bli
oth
ek
 Z
ür
ich
] a
t 0
4:2
2 1
1 J
an
ua
ry
 20
18
 
inﬂammatory stimuli.12 The availability of cognate antigens is cru-
cial for the generation of a GC reaction, however, it is not known
whether antigen load has an impact also on the induction and/or
maintenance of TLS. Mismatch-repair-deﬁciency in CRC causes
microsatellite instability (MSI) and increases the number of neo-
antigens comparing to microsatellite-stable (MSS) tumors. As a
consequence patients with MSI mCRC respond to treatment with
checkpoint inhibitors.13 The development of CRC-associated TLS
tends to be increased in MSI tumors.14 Furthermore, BRAF and
KRAS are frequently mutated in CRC and such alterations can be
recognized by patient’s T cells.15,16 Nevertheless, TLS predict
improved survival in untreated CRC patients independently of
patient characteristics, MSI and other molecular variables.9 Silina
et al. demonstrated that the development of TLS in lung squamous
cell carcinoma (LSCC) follows sequential maturation stages lead-
ing to the formation of GCs. The development of GCs was neces-
sary for the prognostic potential of tumor-associated TLS and was
the most signiﬁcant independent prognostic marker in untreated
LSCC patients.17 It is not known, however, whether TLS matura-
tion has the same relevance and follows the same process in other
tumor types. Furthermore, it is unknown whether the increased
antigen load in MSI and oncogene-mutated tumors inﬂuences
development and maturation of TLS. Finally, the relevance of TLS
maturation as prognosticator for relapse has not been studied.
To address these questions, we explored TLS maturation
stages and their association with patient characteristics, muta-
tion status, and blood based biomarkers of systemic inﬂamma-
tory response in a cohort of patients with stage II and III
colorectal cancer. We examined the prognostic relevance of
TLS maturation and developed a TLS immunoscore that inte-
grates TLS numbers and maturation parameters. We found
that the TLS immunoscore predicts the risk of recurrence in
nmCRC, thus enabling the identiﬁcation of patients with a high
or low anticipated beneﬁt from adjuvant chemotherapy.
Results
Analysis at baseline and crude event rates
One hundred nine patients with non-metastatic CRC were
included in this retrospective cohort study at the time of sur-
gery (Table 1). Ten (24%) of the 42 patients with UICC stage II
disease and 62 (90%) of the 69 patients with UICC stage III
disease received adjuvant chemotherapy (p<0.0001). A highly-
instable microsatellite status (MSI-H) was present in 10
patients (9%), and the BRAF V600E mutation was detected in
10 patients (9%). A strong association between BRAF mutation
and microsatellite status was observed, with 5 (50%) out of the
10 patients with the BRAF mutation also having an MSI-H
status and vice versa (x2 p<0.0001).
During the 3-year follow-up period, we observed 17 recur-
rences (i.e. the primary endpoint, comprising 3 local recur-
rences and 14 occurrences of distant metastasis) and 10
patients died. Six of these deaths were adjudicated to tumor
and 4 deaths to other causes. Sixty-eight (77%) of the patients
that did not develop recurrence or die were followed-up for the
full 3-year period, the remaining 20 patients had a median fol-
low-up of 1.4 years. In competing risk analysis, the cumulative
1-year, 2-year, and 3-year incidences of recurrence were 8.4%
(95%CI: 4.1–14.6), 15.6% (9.4–23.3), and 16.7% (10.2–24.6),
respectively (Supplementary Figure 1). The rate of recurrence
peaked around 1 year after surgery and then rapidly declined
(Supplementary Figure 2).
TLS form in most CRCs
TLS formed in tumor periphery (Fig. 1A) in 97% of patients
(Fig. 1B). The number of TLS per millimeter of tumor invasive
Table 1. Baseline characteristics of the study population (n D 109). Summary esti-
mates represent medians [25th-75th percentile] for continuous variables and abso-
lute counts (%) for categorical variables. Abbreviations: BMI – Body mass index,
ECOG – Eastern Cooperative Oncology Group, L1 – Lymphatic invasion, V1 – Vascu-
lar invasion, MSI – Microsatellite instability status, UICC – Union Internationale pour
le lutte contre le cancer TLS/mm – TLS count, ECOG – Eastern Cooperative Oncol-
ogy Group, % E-TLS – Proportion of Early tertiary lymphoid structure (TLS),
Q1 – 25th percentile of the variable’s distribution (i.e. quartile 1 (Q1)), % PFL-TLS –
Proportion of primary follicle-like TLS, % SFL-TLS – Proportion of secondary folli-
cle-like TLS, GC – Germinal center, EB – Empirical Bayes, ITIS – Integrated TLS
ImmunoScore, CART – Classiﬁcation and Regression Tree, G/L – 109/liter.
Variable N (%missing) Summary estimate
Demographic parameters
Female sex 109 (0.0%) 52 (47.7%)
BMI 103 (5.5%) 25.9 [23.0–28.2]
Age at study entry 109 (0.0%) 64.8 [57.3–74.9]
Family history of cancer 77 (29.4%) 5 (6.5%)
Diabetes 108 (0.9%) 11 (10.2%)
Smoking 80 (26.6%) 13 (16.3%)
Karnofsky index 106 (2.7%) N/A
—100% N/A 72 (67.9%)
—90% N/A 23 (21.7%)
—80% N/A 9 (8.5%)
—70% N/A 1 (0.9%)
—60% N/A 1 (0.9%)
ECOG performance status> 0 106 (2.7%) 34 (32.1%)
Tumor characteristics
Tumor localization 109 (0.0%) N/A
—Cecum, Appendix, Ascending Colon,
Right Flexure, Right Transerve Colon
N/A 36 (33.0%)
—Left Transverse Colon, Left Flexure,
Descending Colon, Sigma
N/A 28 (25.7%)
—Rectum N/A 38 (34.9%)
—Two or more synchronous CRCs N/A 7 (6.4%)
Right sided tumor 109 (0.0%) 36 (33.0%)
L1 109 (0.0%) 19 (17.4%)
V1 109 (0.0%) 12 (11.0%)
MSI high 108 (0.9%) 10 (9.3%)
B-RAF mutant 107 (1.8%) 10 (9.4%)
Tumor grade 109 (0.0%) N/A
—G1 N/A 6 (5.5%)
—G2 N/A 52 (47.7%)
—G3 N/A 51 (46.8%)
Tumor stage 109 (0.0%) N/A
—UICC Stage II N/A 41 (37.6%)
—UICC Stage III N/A 68 (62.4%)
Adjuvant chemotherapy 109 (0.0%) 71 (65.1%)
TLS parameters
TLS/mm 109 (0.0%) 0.5 [0.2–0.9]
% E-TLS 106 (2.7%) 56 [40–78]
% PFL-TLS 106 (2.7%) 20 [6–36]
% SFL-TLS 106 (2.7%) 15 [0–32]
1 GC-harboring TLS 109 (0.0%) 68 (62%)
Immune_context EB prediction 109 (0.0%) ¡0.06 [-0.93–0.61]
ITIS 106 (2.7%) ¡0.1 [-15.4–11.1]
ITIS  CART cut-off 106 (2.7%) 33 (31.1%)
Laboratory parameters
Absolute leukocyte count (G/L) 109 (0.0%) 7.1 [5.9–8.5]
Absolute platelet count (G/L) 109 (0.0%) 290 [242–360]
Absolute neutrophil count (G/L) 105 (3.7%) 4.9 [3.9–6.0]
Absolute lymphocyte count (G/L) 105 (3.7%) 1.3 [1.1–1.7]
Neutrophil-lymphocyte-ratio (units) 105 (3.7%) 3.4 [2.6–4.8]
e1378844-2 F. POSCH ET AL.
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front, here referred to as TLS density, ranged from 0 to 3
(median: 0.5 TLS/mm [25th-75th percentile: 0.2–0.9]). To deter-
mine if genetic alterations bearing immunogenic potential
affect TLS development in CRC, we compared TLS density in
tumors with high microsatellite instability (MSI-H) and/or
BRAF mutations versus tumors not harboring these features.
We observed a signiﬁcantly higher TLS density in tumors
with these molecular features (median: 0.61 vs. 0.45, rank-sum
p D 0.03, Fig. 1C). Further, TLS density positively correlated
with the absolute peripheral lymphocyte count (Spearman’s
rho D 0.27, p D 0.006), and negatively correlated with the
blood-based neutrophil-lymphocyte-ratio (NLR), a marker of
systemic chronic inﬂammation (rho D -0.26, p D 0.007). We
did not observe differences in TLS density with respect to
tumor grade and stage, performance status, or age (Supplemen-
tary Table 1).
Characteristics of TLS maturation in CRC
We detected three distinct phenotypes of TLS representing
different stages of maturation in CRC: (1) early TLS (E-TLS,
dense lymphocytic aggregates without differentiated FDCs),
(2) primary follicle-like TLS (PFL-TLS, B cell clusters with
FDC network but without germinal centers (GCs)), and (3)
secondary follicle-like TLS (SFL-TLS, with GCs) (Fig. 2A).
We calculated the proportion of each TLS maturation stage in
each patient and correlated with different clinical parameters.
The proportion of mature SFL-TLS correlated with the total
TLS density (Spearman rho D 0.41, p<0.0001). NLR nega-
tively correlated with the SFL-TLS proportion (rho D -0.31,
p D 0.002) while positively correlating with the proportion of
the more immature E-TLS (rho D 0.20, p D 0.04). We studied
in detail the differences of TLS maturation in patients with
different TLS densities and found that TLS maturation was
arrested at the E-TLS stage in tumors with low TLS density
(Fig. 2B, left). This in turn resulted in signiﬁcantly decreased
proportions of the PFL and SFL-TLS stages (Fig. 2B, middle
and right).
Because the total TLS density was associated with tumor
mutation status (Fig. 1C), we compared the density of each
maturation stage in these patient groups. Here, patients with
MSI-H and/or BRAF mutated tumors showed higher numbers
of all TLS stages, especially SFL-TLS (Fig. 2C). Associations
were similar when considering each molecular characteristic
separately (Supplemental Figure 3).
TLS characteristics predict CRC recurrence
We used all TLS variables, namely TLS density and the propor-
tions of E-TLS, PFL-TLS, and SFL-TLS, to generate distinct patient
subgroups in order to compare the cumulative incidence of recur-
rence. In the absence of validated cut-offs, these variables were
dichotomized into binary variables using an empirical cut-off at
the 25th percentile of their distribution (Q1), with values  this
cut-off deﬁning the “low” group. For E-TLS, we used a cut-off at
the 75th percentile (Q3) to deﬁne a “high” group, because high
rather than low proportion of E-TLS indicates to impaired TLS
maturation. For all time-to-event analyses, we used proportions
rather than crude numbers of E-TLS, PFL-TLS, and SFL-TLS,
because we considered proportions more reﬂective of the relative
TLS composition within patients.
In univariable competing risk analysis, TLS/mm, E-TLS,
and PFL-TLS showed a strong trend of association with
recurrence risk (Fig. 3A-C, Table 2), while the cumulative
risk of recurrence was signiﬁcantly higher in patients with
low SFL-TLS. In detail, CRC recurrence risk was 31.0% and
9.5% in patients with low and high SFL-TLS proportion
(Gray’s test p D 0.006, Fig. 3D), respectively. Similar data
were obtained in univariable competing risk regression
(Table 3). Here, the relative risk of recurrence was 3.7-fold
higher in patients with low SFL-TLS (SHR D 3.73, 95%CI:
1.39–10.00, p D 0.009), respectively.
After multivariable adjustment for age, ECOG performance
status, stage and adjuvant chemotherapy, low SFL-TLS was
associated with a 4-fold higher risk of recurrence (adjusted
SHR for low SFL-TLS D 3.99, 95%CI: 1.30–12.20, p D 0.015,
multivariable model #4 in Table 4). In multivariable analysis,
all other TLS parameters were also strongly associated with
recurrence risk (multivariable models #1-#3 in Table 4).
Among the included covariates, both low ECOG performance
status and high age were independently associated with recur-
rence. Here, an ECOG performance status > 0 and age 
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Figure 1. Tertiary lymphoid structures in stage II and III colorectal cancer. (A) The presence of TLS was analyzed in 109 CRC tissues by immunoﬂuorescence and identiﬁed
as dense B cell (CD20) aggregates. TLS near the invasive margin (white dashed line) of a CRC (T) and blood vessels (white stars). TLS with a central GC morphology (white
arrowheads) or without (blue arrowheads) were counted. (B) The density of TLS in each patient was determined as the number of TLS per millimeter of tumor invasive
front. (C) Comparison of TLS density in CRC patients with known MSI and BRAF mutation status. MSI-H and/or BRAF mutated CRCs (Mut-Hi, nD 15) were compared versus
patients with wild type BRAF and MSS status (Mut-Lo, n D 94) by Wilcoxon rank-sum test.
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75 years were associated with a 5.8-fold higher and 4.9-fold
higher risk of recurrence, respectively (multivariable model
#4 in Table 4). TLS parameters were also independently prog-
nostic after adjusting for the MSI and BRAF mutation status
(Supplementary Table 2).
Our analysis treats E-TLS, SFL-TLS, PFL-TLS as propor-
tions reﬂecting TLS maturity. To investigate whether not only
these relative measures of TLS maturation but also absolute
TLS maturity parameters harbor prognostic information on
CRC recurrence, we investigated the association between the
presence of at least one TLS harboring an active GC reaction
and CRC recurrence risk. In detail, the absolute 3-year risk of
CRC recurrence was 9.5% in the 68 patients (62%) who had at
least one GC-harboring TLS, as compared to 28.5% in the 41
patients (38%) who did not have any GC-harboring TLS
(Fig. 4; corresponding to a 70% lower relative risk of recur-
rence: SHR D 0.30 (95%CI: 0.11–0.79, p D 0.015; Table 3)).
This association also fully prevailed upon multivariable adjust-
ment for age, performance status, adjuvant chemotherapy,
and tumor stage (Adjusted SHR D 0.28, 95%CI: 0.09–0.84,
p D 0.024; multivariable model #5 in Table 4).
An Integrated TLS ImmunoScore (ITIS) predicts
the recurrence risk in CRC
Based on these results, we hypothesized that the integration of
TLS density and TLS maturation would provide a higher pre-
dictive power for CRC recurrence risk than each TLS parameter
separately. We used structural equation modeling and devel-
oped an integrated TLS immunoscore (ITIS) to analyze TLS
density and relative abundance of maturation stages as a joint
parameter. In detail, we assumed a latent variable (immune_-
context), which predicts for 3-year time-to-recurrence (time2-
mets), and is informed by four continuous measures, namely
total TLS density (TLSmm), and the proportions of E-TLS
(E_TLS), PFL-TLS (PFL_TLS), and SFL-TLS (SFL_TLS, Fig. 5).
In this model, all four measures signiﬁcantly loaded onto the
latent variable (TLSmm p D 0.01, all others p<0.0001), with
E-TLS being associated with a decrease in the latent variable
and all other variables being associated with an increase in the
latent variable (Supplementary Table 3). Further, the latent var-
iable (distribution reported in Table 1) signiﬁcantly predicted
for a lower risk of recurrence (Hazard ratio per 1 standard devi-
ation increase D 0.58, 95%CI: 0.38–0.89, p D 0.013).
We then applied the path coefﬁcients of the model’s mea-
surement component (Supplementary Table 3) to construct the
ITIS (distribution reported in Table 1 and Supplementary
Fig. 4), deﬁned as the sum of the products of the path coefﬁ-
cients and their observations in our cohort, standardized by
their intercept (Equation 1):
ITIS D 0:11  TLSmm
0:63
¡ 18:68  E_TLS
56:12
C 9:76  PFL_TLS
24:33
C 8:92  SFL_TLS
19:56
Cancelling out the denominators, the ITIS reduces to Equation
2:
ITIS D 0:18  TLSmm--0:33  E_TLSC 0:40  PFL_TLS
C 0:46  SFL_TLS
This score aligned well with the latent “immune_context” vari-
able (Spearman’s rho D 0.996, p<0.0001, Supplementary
Figure 5).
The cumulative 3-year risks of recurrence were 31.7%
(95%CI: 17.2–47.3), 9.8% (2.5–23.3), and 9.4% (2.4–22.4) in
Figure 2. Tertiary lymphoid structure maturation in stage II and III colorectal can-
cer. (A) The composition of TLS was analyzed by multi-parameter immunoﬂuores-
cence using serial tissue sections of CRC. Two sets of antibodies were combined to
visualize (1) the spatial organization of B cells (CD20), T cells (CD3), and CCL21 (top
row), and (2) TLS maturation by the presence of FDCs (CD21), germinal center (GC)
B cells (CD23), and CXCL13 (bottom row). (B) Different maturation stages were
assessed by multiparameter immunoﬂuorescence in CRC tissues. TLS in each matu-
ration stage (E-TLS – dense lymphocytic clusters: CD21¡CD23¡, PFL-TLS – clusters
with an FDC network: CD21CCD23¡, SFL-TLS – clusters with active GC reaction:
CD21CCD23C) were counted for each patient and expressed as the proportion of
the total TLS count. The proportions of the three maturation stages were com-
pared in patients with high (n D 84) and low (n D 25) TLS density (cut-off at the
25th percentile of TLS density distribution (i.e. Q1)) by a Wilcoxon rank-sum test.
(C) The density of each TLS maturation stage was compared for patients with
mutated BRAF and/or MSI-H status (Mut-hi, n D 15) versus patients with wild type
BRAF and MSS status (Mut-lo, n D 94) by a two-tailed Mann-Whitney U test.
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patients in the 1st, 2nd, and 3rd tertile of the ITIS distribution,
respectively (Gray’s test p D 0.01, Fig. 6A). These tertile cut-
offs were chosen empirically in the absence of established
cut-offs. In competing risk regression, a higher ITIS (as a con-
tinuous variable) was signiﬁcantly associated with a lower risk
of the primary endpoint (SHR for 10 units increase D 0.73,
95%CI: 0.55–0.95, p D 0.02), and this association prevailed in
multivariable analysis adjusting for age, ECOG performance
status, stage, and adjuvant chemotherapy (multivariable model
#6 in Table 4).
Further, we did not observe an interaction between ITIS and
stage (UICC II vs. UICC III, p for interaction D 0.74), suggest-
ing that the ITIS may be comparably relevant for both stages.
To further investigate this, we performed a subgroup analysis
by stage where we Z-standardized the ITIS within stage. ITIS
showed a similar relative association with recurrence risk in
patients with stage II disease (SHR per 1 SD increase D 0.48,
95%CI: 0.19–1.22, p D 0.12) and stage III disease (SHR per 1
SD increase D 0.60, 95%CI: 0.33–1.07, p D 0.08). Although the
subgroup analyses were not signiﬁcant due to lower numbers
of cases within stages, the comparable magnitude of the regres-
sion coefﬁcients suggest that ITIS may be similarly relevant in
stage II and stage III patients. Moreover, we also did not
observe an interaction with adjuvant chemotherapy (p D 0.97).
Potential time-dependent associations of the ITIS were
investigated by ﬁtting interactions between the ITIS and lin-
ear-follow-up time, which suggested that the protective
association of a high TLS immunoscore slightly weakened
with time (p for interaction D 0.009). In detail, the SHRs
for 10 units increase in ITIS were estimated at 0.50 (95%CI:
0.28–0.88, p D 0.02), 0.62 (95%CI: 0.44–0.89, p D 0.01),
0.69 (95%CI: 0.50–0.96, p D 0.05), and 0.70 (95%CI: 0.53–
0.93, p D 0.01) after 6, 12, 18, and 24 months of follow-up,
respectively.
Finally, a classiﬁcation and regression tree (CART) analysis
was performed to investigate the strongest recurrence risk
Gray's test p=0.0900
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Figure 3. Tertiary lymphoid structure parameters and 3-year risk of colorectal cancer recurrence. Patients with low TLS counts (A), high proportions of E-TLS (B), and low
proportions of PFL-TLS (C) showed a tendency towards numerically higher risks of recurrence. Patients with low SFL-TLS proportion (D) experienced a signiﬁcantly higher
risk of recurrence. Absolute risk estimates corresponding to these curves are reported in Table 2. Recurrence risks were estimated with competing risk analysis, treating
death-from-any-cause as the competing event of interest. In the risk table, numbers in brackets represent the number of recurrences in the respective time interval.
Abbreviations: Q1 – Cut-off at the 25th percentile of the variables’ distribution (i.e. quartile 1), Q3 – Cut-off at the 75th percentile of the variable’s distribution (i.e. quartile
3).
Table 2. TLS variables and 3-year recurrence risk. Risks were estimated with competing risk cumulative incidence estimators, treating death-from-any-cause as the com-
peting event of interest.   and < Q3 for % E-TLS. Abbreviations: Q1 – 25th percentile of the variable’s distribution (i.e. quartile 1 (Q1)), TLS/mm – TLS count, % E-TLS –
Proportion of Early tertiary lymphoid structure (TLS), % PFL-TLS – Proportion of primary follicle-like TLS, % SFL-TLS – Proportion of secondary follicle-like TLS.
Variable 3-year recurrence risk in patients  Q1 (95%CI) 3-year recurrence risk in patients> Q1 (95%CI) Gray’s test p-value
TLS/mm 25.2% (11.1–42.0) 13.7% (7.0–22.6) 0.090
% E-TLS 27.5% (12.1–45.4) 13.6% (7.0–22.5) 0.101
% PFL-TLS 25.9% (11.5–43.1) 14.4% (7.3–23.7) 0.075
% SFL-TLS 31.0% (16.7–46.4) 9.5% (3.9–18.3) 0.006
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predictors in our dataset and explore optimal cut-offs for deﬁn-
ing patients with a low ITIS. The CART algorithm selected
ECOG status and ITIS as the two strongest predictors of recur-
rence risk, and suggested a cut-off for low ITIS at -12 ITIS
points (Supplementary Figure 6). In multivariable competing
risk regression, patients with a low ITIS had an eight-fold
higher risk of recurrence than patients above this cut-off,
respectively (multivariable model #7 in Table 4). The corre-
sponding 3-year recurrence risk was 34.7% (95%CI: 18.9–51.1)
for patients with low ITIS, and 9.1% (95%CI: 3.7–17.6) for
patients with high ITIS, respectively (Gray’s test p D 0.02,
Fig. 6B). Thus, the ITIS is a stronger indicator of recurrence
risk than the analyzed TLS parameters individually.
Discussion
It is of paramount clinical interest to predict the risk of recur-
rence in nmCRC in order to personalize the selection of
patients for adjuvant chemotherapy. The determinants of an
effective anti-tumor immune-surveillance leading to long-term
freedom from recurrent disease after complete cancer resection
in nmCRC are not yet fully understood.18 The composition of
the immune cell inﬁltrate has repeatedly been shown to be
prognostic in a variety of cancer types.19 Speciﬁcally for CRC,
the Immunoscore derived from the number of tumor-inﬁltrat-
ing T cells5 has been validated in a large multicenter study as a
signiﬁcant prognosticator of stage I/II/III disease.20 Further, the
presence of lymphatic vessels and cytotoxic T cells rather
than the genetic alterations of primary CRCs predict the devel-
opment of metastatic disease.21 The number of TILs
signiﬁcantly correlates with TLS in CRC,8,22,23 however it is still
not clear whether the two parameters are interdependent.
Several TLS-associated cell types like mature DCs, B cells, T
follicular helper cells and high endothelial venules have been
used as surrogates to quantify TLS in cancer tissues. No matter
the method, the large majority of studies report a positive asso-
ciation between TLS and survival in CRC and other tumor
types.24 Here we applied a quantitative pathology approach to
detect TLS as a whole structure rather than using surrogate
markers. We observed that peritumoral TLS exhibited strong
phenotypic differences both within and between patients based
on their capacity to recruit FDCs and generate GCs, which sup-
ports the concept of sequential TLS maturation steps with
increasing B-cell activity. This is in agreement with the observa-
tions in LSCC (Silina et al. in revision) and suggests that TLS
maturation follows a similar process in different cancers.
In exploring the prognostic potential of the different TLS
maturation populations, we studied their association with dis-
ease recurrence after surgery in curative intent in nmCRC.
Here, we observed that patients with a higher density of mature
TLS had a four-fold lower risk of recurrence. Further, the pro-
portion of TLS with FDCs and GCs showed a stronger
association with recurrence risk than mere TLS density. In
addition to these proportions, also the presence of at least on
GC-harboring TLS was associated with a much lower risk of
CRC recurrence. These data are in line with the survival study
Table 3. Univariable competing risk regression models of 3-year recurrence risk. Results were estimated with univariable Fine & Gray competing risk regression models,
treating death-from-any-cause as the competing event of interest. Abbreviations: SHR – Subdistribution hazard ratio, 95%CI – 95% conﬁdence interval, BMI – Body mass
index, ECOG – Eastern Cooperative Oncology Group, L1 – Lymphatic invasion, V1 – Vascular invasion, MSI – Microsatellite instability status, UICC – Union Internationale
pour le lutte contre le cancer TLS/mm – TLS count, ECOG – Eastern Cooperative Oncology Group, % E-TLS – Proportion of Early tertiary lymphoid structure (TLS), Q1 –
25th percentile of the variable’s distribution (i.e. quartile 1 (Q1)), % PFL-TLS – Proportion of primary follicle-like TLS, % SFL-TLS – Proportion of secondary follicle-like TLS,
GC – Germinal center, EB – Empirical Bayes, ITIS – Integrated TLS ImmunoScore, CART – Classiﬁcation and Regression Tree, G/L – 109/liter.
Variable SHR 95%CI p
Demographic variables
Female sex 0.58 0.22–1.57 0.283
BMI (per 5 kg/m2 increase) 0.57 0.29–1.12 0.105
Age at study entry  75 years 3.97 1.54–10.21 0.004
Smoking 0.92 0.20–4.24 0.916
ECOG performance status> 0 7.85 2.54–24.28 <0.0001
Tumor variables
Right sided tumor 1.14 0.42–3.08 0.794
L1 1.38 0.47–4.01 0.554
V1 1.08 0.23–5.13 0.925
MSI high 0.54 0.07–3.90 0.538
B-RAF V600E mutant 0.54 0.08–3.67 0.532
Tumor grade G3 2.14 0.80–5.76 0.130
UICC tumor stage III 2.02 0.65–6.25 0.222
Adjuvant chemotherapy 1.23 0.42–3.59 0.710
Immune contexture variables
TLS/mm  Q1 2.24 0.84–5.92 0.106
% E-TLS  Q3 2.21 0.85–5.77 0.104
% PFL-TLS  Q1 2.24 0.83–6.06 0.111
% SFL-TLS  Q1 3.73 1.39–10.00 0.009
1GC-harboring TLS 0.30 0.11–0.79 0.015
Immune_context EB prediction(per 1 unit increase) 0.54 0.34–0.86 0.010
ITIS (per 10 units increase) 0.73 0.55–0.95 0.020
ITIS  CART cut-off 4.83 1.82–12.85 0.002
Laboratory parameters
Absolute leukocyte count (per 1 G/L increase) 0.91 0.78–1.07 0.264
Absolute platelet count (per 50 G/L increase) 0.79 0.62–1.00 0.052
Absolute neutrophil count (per 1 G/L increase) 0.94 0.81–1.08 0.368
Absolute lymphocyte count (per 1 G/L increase) 0.41 0.19–0.86 0.019
Neutrophil-lymphocyte-ratio (per 5 units increase) 1.00 0.73–1.35 0.975
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in neo-adjuvant chemotherapy treated LSCC patients. There,
TLS had almost no GCs and TLS counts had no prognostic sig-
niﬁcance in comparison to untreated patients where TLS fre-
quently had GCs and were the most important independent
prognostic marker.17 These data suggest further hypotheses: (1)
TLS with a GC reaction represents the most “functional” sub-
type, (2) GC development indicates towards tumor-speciﬁc B
cell and CD4 T cell priming, and (3) TLS maturation harbors
additional information to mere TLS enumerations for the prog-
nosis of CRC recurrence.
To address the latter, we summarized both the number and
maturity of peritumoral TLS into an integrated TLS immuno-
score (ITIS). Elevated ITIS identiﬁed a large patient subgroup
(two thirds of our study cohort) with a very low risk of recur-
rence independently of the current most relevant predictors
such as ECOG performance status, pathologic tumor stage,
adjuvant chemotherapy, MSI status and age. These data suggest
a potential relevance of both TLS numbers and maturation for
the immune control of nmCRC. If validated in external pro-
spective cohorts, the ITIS could have important implications
for identifying an nmCRC subpopulation in which adjuvant
chemotherapy may be safely avoided. We did not examine the
association between TLS parameters and survival, because the
event rate for mortality was low and diluted by deaths from
Table 4. Multivariable competing risk regression models of 3-year recurrence risk. Results were estimated with multivariable Fine & Gray competing risk regression mod-
els, treating death-from-any-cause as the competing event of interest. Abbreviations: SHR – Subdistribution hazard ratio, 95% CI – 95% conﬁdence interval, TLS/mm –
TLS count, ECOG – Eastern Cooperative Oncology Group, UICC – Union Internationale pour le lutte contre le cancer, % E-TLS – Proportion of Early tertiary lymphoid struc-
ture (TLS), Q1 – 25th percentile of the variable’s distribution (i.e. quartile 1 (Q1)), % PFL-TLS – Proportion of primary follicle-like TLS, % SFL-TLS – Proportion of secondary
follicle-like TLS, GC – Germinal center, ITIS – Integrated TLS ImmunoScore, CART – Classiﬁcation and Regression Tree.
Model Variable SHR 95%CI p
Multivariable Model #1 TLS/mm  Q1 4.09 1.32–12.71 0.015
Age  75 years 5.40 1.71–17.01 0.004
ECOG performance status> 0 8.06 2.69–24.10 <0.0001
UICC tumor stage III 2.32 0.76–7.05 0.138
Adjuvant chemotherapy 2.05 0.57–7.36 0.269
Multivariable Model #2 % E-TLS  Q3 4.01 1.39–11.55 0.010
Age  75 years 4.85 1.90–12.40 0.001
ECOG performance status> 0 7.39 2.16–25.34 0.001
UICC tumor stage III 1.90 0.48–7.60 0.362
Adjuvant chemotherapy 1.21 0.30–4.81 0.786
Multivariable Model #3 % PFL-TLS  Q1 4.28 1.59–11.54 0.004
Age  75 years 3.94 1.26–12.27 0.018
ECOG performance status> 0 6.94 1.66–28.92 0.008
UICC tumor stage III 2.16 0.58–8.01 0.250
Adjuvant chemotherapy 1.80 0.48–6.77 0.385
Multivariable Model #4 % SFL-TLS  Q1 3.99 1.30–12.20 0.015
Age  75 years 4.88 1.75–13.58 0.002
ECOG performance status> 0 5.77 1.90–17.54 0.002
UICC tumor stage III 3.50 0.96–12.71 0.057
Adjuvant chemotherapy 0.92 0.29–2.94 0.889
Multivariable Model #5 1 GC-harboring TLS 0.28 0.09–0.84 0.024
Age  75 years 4.61 1.69–12.54 0.003
ECOG performance status> 0 6.98 2.25–21.68 0.001
UICC tumor stage III 2.96 0.86–10.12 0.084
Adjuvant chemotherapy 1.09 0.37–3.23 0.871
Multivariable Model #6 ITIS (per 10 units increase) 0.67 0.49–0.92 0.012
Age  75 years 4.86 1.76–13.42 0.002
ECOG performance status> 0 6.03 1.85–19.67 0.003
UICC tumor stage III 2.10 0.42–10.51 0.366
Adjuvant chemotherapy 1.29 0.26–6.40 0.753
Multivariable Model #7 Low ITIS (i.e. CART cut-off) 8.41 2.73–25.87 <0.0001
Age  75 years 6.06 2.18–16.85 0.001
ECOG performance status> 0 8.80 2.69–28.78 <0.0001
UICC tumor stage III 1.47 0.36–6.03 0.594
Adjuvant chemotherapy 1.31 0.31–5.50 0.709
Gray's test p=0.0120
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Figure 4. Competing risk analysis of germinal-center-harboring TLS and 3-year risk
of colorectal cancer recurrence. Cumulative incidences of recurrence were derived
with competing risk analysis, accounting for death-from-any-cause as the compet-
ing risk of interest. Patients were dichotomized into two groups according to
whether they had at least one TLS with an active GC reaction (n D 68) or not
(nD 41). Risktables (“Number at risk”) report the number of patients in each group
at risk of recurrence at the start of each time interval. The number of recurrences in
each time interval (“Recurrences”) are reported in brackets.
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causes other than CRC disease progression in our cohort. Fur-
ther, studying the relationship between ITIS and the Immuno-
score will allow assessing their interdependence and potentially
yield improved immune-based prognostic tools.
We applied a statistical technique called generalized struc-
tural equation modeling (SEM) to generate ITIS. SEM is widely
used in the ﬁeld of psychology to test whether highly correlated
data are consistent with an underlying, abstract, unobservable
or difﬁcult-to-observe “latent” process.25 For example, the
intelligence quotient (IQ) is a typical latent variable generated
by SEM based on test participants’ answers to the different
questions of an IQ test. Likewise, we estimated the ITIS as a
latent variable reﬂecting TLS formation and maturation by our
patients’ TLS counts and relative proportions of E-TLS, PFL-
TLS, and SFL-TLS. Our data show that SEM is a powerful
approach for analyzing joint signatures of biomarkers in immu-
nology. Studies in the ﬁeld of immunology often assess multiple
immune markers at the same time, which may not only yield
more insights but can also inﬂate type I error rates and make a
joint interpretation of results challenging. SEM can estimate
latent variables that summarize these multiple immune
markers, and study their joint association with other (non-)
immune variables and clinical outcomes such as cancer recur-
rence or disease progression. The concept of using SEM for
immune_context
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Figure 5. Path diagram of the structural equation model for estimating the relationship between TLS parameters, a latent TLS immune contexture variable, and colorectal
cancer recurrence. Numbers to the right of the path represent path coefﬁcients (or the log(hazard ratio) for the path from “immune_context” to “time2mets”)). Numbers
in the right bottom of the square boxes represent the intercepts of the path coefﬁcients. Numbers adjacent to the round error terms represent the errors of the measure-
ments. Abbreviations: TLSmm – TLS count, E-TLS – Early TLS proportion, PFL-TLS – primary follicle like TLS proportion, SFL-TLS – secondary follicle like TLS proportion.
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immunology research was ﬁrst proposed in 2011 by Brown and
colleagues.26 However, only a few studies have made use of this
technique so far. For example, Baltar et al. used SEM for exam-
ining the relationships between B vitamins and immune
markers in lung cancer pathogenesis.27 Recent software devel-
opments in the ﬁeld will considerably improve the accessibility
of SEM methods to a wide group of scientists beyond biostatis-
ticians.28 Therefore, our analysis could serve as a template for
future studies assessing prognostic and predictive biomarker
signatures in the ﬁeld of immuno-oncology.
In CRC patients, the mutation load inﬂuences tumor
antigenicity and is associated with tumor immune recognition
and efﬁcacy of immunotherapy.29,30 MSI is associated with
increased tumor antigen load and increased tumor immunoge-
nicity that is crucial for the success of anti-PD-1 therapy in
mCRC.13 However, also a part of MSS CRC patients respond to
such therapy by combining different treatment strategies.31
Apart from MSI, also mutations in oncogenes such as BRAF
and KRAS yield immunogenic epitopes.15,16 However, the rele-
vance of antigen load for the induction or maintenance of
tumor-associated TLS is not clear. To test this we compared
TLS parameters in patients with MSI-H status and/or BRAF
mutations assuming such tumors are enriched with immuno-
genic antigens. We observed that TLS were not only more fre-
quent but also more mature in patients with these genetic
alterations. This suggests that TLS development is facilitated by
the availability of tumor antigens in nmCRC. Whether TLS can
serve as a marker for increased tumor antigenicity and thus bet-
ter identify patients who respond to immunotherapy should be
addressed in future clinical trials. One drawback of our study is
the lack of the analysis of KRAS mutations, which might have
provided a more precise deﬁnition of the low antigen load
tumor group.
Apart from the antigenic load, the local and/or systemic
immunosuppressive milieu affects tumor immunogenicity.32
An elevated neutrophil-lymphocyte ratio (NLR) is an indica-
tion of systemic inﬂammatory response, and is an indepen-
dent poor prognostic marker in multiple tumor types
including CRC.33-36 We observed that high NLR signiﬁcantly
correlated with low TLS density and decreased maturation. It
is not known whether the increased neutrophil numbers have
a direct impact or are an indication of other processes leading
to impaired TLS development in patients with increased NLR.
Nevertheless, we propose that the presence of GC-positive
TLS reﬂects an immunogenic tumor microenvironment.
Although beyond the data of our study and the CRC setting,
we carefully speculate that future studies could focus on inves-
tigating TLS maturation parameters and the ITIS as putative
predictive biomarkers for clinical response to checkpoint
inhibitors.
When considering potential future clinical applications of
the ITIS and the TLS maturation concept, it is important to
note that a low ITIS (as deﬁned by the 1st tertile of the score)
could identify patients with a very high risk of CRC recurrence,
whereas the CRC recurrence risk was low in patients above the
1st ITIS tertile and did not differ between patients in the 2nd
and 3rd ITIS tertile. This “non-linearity” suggests that a low
ITIS may be most useful as a “high-risk” biomarker for identi-
fying a third of stage II/III CRC patients with a strong
propensity for disease recurrence, whereas the ITIS does not
appear to contribute prognostic resolution in the other two
thirds of patients who already have a very low risk of
recurrence.
Some limitations should be considered. First, our study
would have beneﬁted from a larger sample size. In detail, some
associations, which did not meet the pre-speciﬁed criteria for
statistical signiﬁcance of association (p0.05), may have
crossed this signiﬁcance threshold with a slightly higher sample
size and event rate. Second, we did not externally validate our
ﬁndings in a separate cohort of CRC patients. Importantly,
external validation of both the ITIS score and the proposed
cut-offs will be necessary before advancing the concept of TLS
maturation into the clinic. Third, the ITIS was developed for
the stage II and III CRC setting, and does not necessarily gener-
alize to other tumor types, which may feature other absolute
and relative TLS parameter counts. Fourth, the association
between BRAF V600E mutation status and increased TLS for-
mation may have been confounded by the strong associations
between BRAF, MSI, and TLS formation. Although some
reports support an involvement of BRAF mutation status in
adverse prognosis in the adjuvant CRC setting,37,38 our data on
BRAF mutation as a determinant of TLS formation hence have
to be considered as preliminary and require external validation.
Finally, all TLS immunopathology analyses in this study were
performed by a single scientist (KS) at a single academic center
(University Hospital Zurich, Switzerland) who was fully
blinded to the clinical characteristics and outcomes of patients.
Although this can be considered as strength, it still needs to be
demonstrated that the TLS parameter enumeration approach
proposed in this study can successfully be performed in other
laboratories and settings.
Conclusion
In conclusion, this comprehensive analysis of clinical, molecu-
lar, tissue, and blood-based parameters in patients with stage II
and III CRC revealed three novel ﬁndings. First, our data dem-
onstrate the presence of distinct maturation subtypes of TLS in
nmCRC. Second, TLS maturation is an important parameter of
tumor immune contexture and bears signiﬁcant prognostic and
potential predictive value. Notably, the prognostic potential of
TLS maturation for CRC recurrence may be higher than the
potential of plain TLS enumeration. Third, using SEM for the
integration of TLS parameters into a joint immunoscore (ITIS)
allowed identiﬁcation of patient subgroups at high and low risk
of tumor recurrence independent of established prognostic
markers. If validated in external clinical studies, our data may
have important implications for targeted indication of adjuvant
chemotherapy in this highly prevalent tumor entity.
Patients & methods
Study design & patient population
This study represents a single-center, observational, retrospec-
tive cohort study. The study population includes all
patients with histologically-conﬁrmed, UICC stage II or III ade-
nocarcinoma of the colon and rectum who were seen at a large
ONCOIMMUNOLOGY e1378844-9
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tertiary academic oncology center in Middle Europe (Division
of Oncology, Medical University of Graz, Austria) between Jan,
1996 and Jun, 2011 after having had undergone surgery in
curative intent. Patients with evidence of distant metastasis at
the time of diagnosis were excluded, even if a (neoadjuvant)
treatment plan in curative intent was followed.
All patients were routinely examined every 3 months during
the ﬁrst 3 years after surgery within the aftercare program of
the Medical University of Graz’ Division of Oncology. During
each of these visits a detailed medical history, physical exami-
nation and full laboratory investigation was performed. At
every second visit a chest-X-ray and abdominal ultrasound was
performed. For the current study we retrospectively included
only those patients who had a valid local biobank consent per-
mitting the unconditional storage and subsequent analysis of
their primary tumor tissue samples, which resulted in 111
patients. TLS analysis was unsuccessful in 2 of these patients,
resulting in a ﬁnal study population of 109 patients.
Baseline and outcome data were collected retrospectively
from our in-house electronic healthcare database and from
written documents of the oncologic outpatient department as
previously reported.39,40 The primary endpoint of this study
was 3-year disease recurrence, deﬁned as the cumulative inci-
dence of local recurrence and/or distant metastasis within the
ﬁrst 3 years after surgery accounting for death-from-any-cause
as a competing event. This research was approved by the Ethics
Committee and the biobank at the Medical University of Graz
(vote number: 26–196 ex 13/14). The Ethics Committee
granted us a “waiver of consent” for this retrospective study
consistent with national legal regulations, i.e. no individual
consent was required from included patients.
Analysis of TLS maturation stages
The sample analyst (KS) was fully blinded to the clinical char-
acteristics and outcomes of patients. FFPE tumor blocks were
used to prepare 2-mm thick serial sections and used for multi-
parameter immunoﬂuorescence (IF) staining. TLS maturation
stages were analyzed in all patients by the detection of FDCs
(CD21), GCs (CD23) and CXCL13 using the thyramide signal
ampliﬁcation (TSA) approach according to manufacturer’s
protocol (PerkinElmer). IF was performed using the Discovery
Ultra automated systems (Ventana Medical Systems, USA)
according to the standard operating procedure at the University
Hospital Zurich. Slides were mounted using Vectashield Anti-
fade Mounting Medium with DAPI (Vector Laboratories).
The slides were scanned using the automated multispectral
microscopy system Vectra 3.0 (PerkinElmer). Whole slide scan
was performed at 100x magniﬁcation and multispectral high
power ﬁelds were imaged at 200x. An unstained nmCRC slide
was used to generate the spectral proﬁle of autoﬂuorescence in
nmCRC tissues, and single stained slides were used to generate
the spectral proﬁles of the used ﬂuorophores. The Inform soft-
ware (PerkinElmer) was used to unmix the spectra for each
speciﬁc ﬂuorophore from the autoﬂuorescence. More than 90%
of all lymphocytic aggregates were imaged in each patient in
high power, excluding Payer’s patches. TLS were enumerated
in the whole slide including tumor tissue and adjacent normal
tissue. TLS density was calculated as the number of TLS per
mm of tumor-invasive front in peri- and intratumoral regions.
The peritumoral region was deﬁned as the immediate adjacent
non-tumoral tissue within a 7 mm radius of the tumor front.
For each patient, the TLS density estimate was derived from
the tissue block with the highest TLS density. TLS maturation
stages were assessed as described previously by co-staining for
CD21, CD23, and CXCL13:17 (1) early stage (E-TLS), charac-
terized by dense lymphocytic aggregates without CD21 and
CD23 expression, (2) primary follicle-like stage (PFL-TLS),
characterized by lymphocytic clusters with central network of
mature FDCs (CD21C), but no GC reaction (CD23¡), and (3)
secondary follicle-like stage (SFL-TLS), characterized by lym-
phocytic clusters with GC reaction (CD21CCD23C). The num-
bers of TLS in each maturation stage were counted and
expressed as a proportion from all TLS within each patient or
as normalized counts per mm of tumor perimeter. We termed
the total number of TLS per mm of tumor perimeter as TLS
density. The tumor perimeter was measured in the whole slide
image as the gross length of tumor invasive front facing adja-
cent normal tissue by the Fiji software.
Additionally, serial sections from 5 patients with high num-
bers of peritumoral TLS were used to stain for B cells (CD20),
T cells (CD3) and CCL21 to assess the lymphocytic organiza-
tion of TLS in CRC. IF was performed by a manual protocol. In
detail, after heating of slides for 2 hours at 55C, slides were
incubated with the Trilogy pretreatment solution (CellMarque)
for 15 minutes in a pressure cooker. After cooling for 15
minutes and washing in milli-Q water, slides were treated with
3% H2O2, washed with 0.1% Triton X-100 in PBS, and blocked
BSA/0.1% Triton X-100/PBS. Antibodies were diluted in 1%
BSA / 0.1% Triton X-100 / PBS. After overnight incubation of
primary antibodies with slides at 4C, slides were washed and
incubated for 1 hour at room temperature with secondary anti-
bodies. Further, slides were incutabinted with DAPI (Invitro-
gen 0.5 mg/mL) and mounted with the ProlongDiamond
medium (both Life Technologies). Slides were imaged using the
laser-scanning confocal microscope Leica SP8 (Leica). See Sup-
plementary Table 4 for all used antibodies and protocols.
Assessment of BRAF mutation and mismatch-repair status
BRAF V600E mutation status was determined using an allele-
speciﬁc real-time PCR protocol providing a mutation detection
limit of 10 copies of mutant DNA in proportions as low as 1%
of the total DNA as described previously.41 In brief, two sepa-
rate PCRs were performed to assess mutation status: An allele-
speciﬁc PCR utilizing an allele-speciﬁc PCR primer for mutant
allele detection and a mutation unspeciﬁc PCR to generate a
reference amplicon. Target ampliﬁcation during real-time PCR
was detected by a TaqMan probe. Additionally, an exogenous,
internal control PCR product, a fragment in the CYP17 pro-
moter region, was co-ampliﬁed in each reference and allele-spe-
ciﬁc PCR. Used primer sequences are given in Supplementary
Table 5. Reference PCR was performed in a 25ml reaction vol-
ume with 1x TaqMan Genotyping Master Mix (ThermoFisher
Scientiﬁc), 900nM of BRAF mutation-unspeciﬁc primers (for-
ward and reverse), 100nM BRAF probe, 112.5nM of each inter-
nal control primer, 25nM of internal control probe, and 5ml
DNA of varying concentration. Allele-speciﬁc PCRs were
e1378844-10 F. POSCH ET AL.
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performed according to the same protocol, but using a concen-
tration of 450nM of allele-speciﬁc primer. All real-time PCRs
were carried out on a LightCycler  480 Real-Time PCR System
(Roche Diagnostics, Vienna, Austria) under the following ther-
mocycling conditions: 95C for 10 min followed by 50 cycles of
90C for 15 sec and 60C for 1min. Cycle thresholds (Ct) were
recorded for reference PCR as well as for each allele-speciﬁc
PCR and corresponding DCt values (i.e. allele-speciﬁc Ct minus
reference Ct) were calculated. A DCt value of 9 was used as cut-
off point for mutation detection.
MSI analysis was performed immunohistochemically using
antibodies for the mismatch repair proteins MLH1 (clone
G168–15, BD Pharmingen, San Diego, California, USA), PMS2
(clone A16–4, BD Pharmingen, San Diego, California, USA),
MSH2 (clone G219–1129, Cell Marque, Rocklin, California,
USA) and MSH6 (clone SP93, Cell Marque, Rocklin, California,
USA). The histological features of the tumours and the immu-
nohistochemical staining were assessed by a Pathologist (SL)
unaware of the patientsclinical data. Loss of the respective mis-
match repair protein was recorded when nuclear staining was
absent from all tumour cells but preserved in normal epithelial
and stromal cells.
Statistical methods
All statistical analyses were performed using Stata (Windows
version 14.0, Stata Corp., Houston, TX, USA). The statistical
analyst (FP) did not have access to tissue samples or primary
data from tissue analyses. Continuous variables were summa-
rized as medians [25th-75th percentile], whereas count data
were reported as absolute frequencies (%). The association
between two categorical variables was assessed with x2-tests or
Fisher’s exact tests. Means between two or more groups were
compared with Wilcoxon rank-sum tests and Kruskal-Wallis
tests. Correlations between two continuous variables were com-
puted with Spearman’s rank-based correlation coefﬁcient.
Follow-up was deﬁned as the time from the day of surgery
until the occurrence of recurrence, death, or censoring alive
3 years after surgery. The median follow-up time was estimated
with the method of Schemper & Smith.42 Flexible parametric
modeling of the hazard function was applied for estimating
recurrence rates at different time points of follow-up (Stata rou-
tine stpm2).43 A competing risk cumulative incidence estima-
tor, treating death-from-any-cause as a competing risk, was
used for the calculation of 3-year recurrence risk (Stata routine
stcompet).44,45 Gray’s test was used to compare the 3-year
cumulative incidences of recurrence between two or more
groups (self-written Stata routine stgrays using the R library
cmprsk via rsource).46 In the absence of validated cut-offs for
TLS density and TLS maturation parameters, we pre-speciﬁed
to select an empirical cut-off at the 25th percentile to dichoto-
mize patients into subgroups with low relative levels of immune
contexture parameters. Fine & Gray proportional subdistribu-
tion hazards models were ﬁtted for uni- and multivariable
time-to-recurrence regression (Stata routine stcrreg).47 The
proportional subdistribution hazards assumption was assessed
by including products of linear follow-up time and the variable
of interest in the respective models (tvc option in stcrreg).
A generalized structural equation model with time-to-recur-
rence as a Weibull time-to-event response, linked to a latent
variable (m D 0, s2 D 1) via a log-link, was constructed graphi-
cally (Stata’s GSEM builder), and then estimated with a non-
adaptive Gauss Hermite quadrature algorithm (Stata routine
gsem).25,28 The latent variable reﬂects both TLS density and
maturation stages, and in order to simplify its calculation in
practice, we expressed it as an “Integrated TLS immunoscore
(ITIS).” This was achieved by computing the ITIS as the sum of
the products of the path coefﬁcients for the latent variable and
their observation in a patient, standardized by the path coefﬁ-
cients’ intercepts (Equation 1 in the results section).
In sensitivity analyses, we (1) performed a classiﬁcation and
regression tree analysis (CART, Stata routine cart) to explore
the strength of recurrence risk predictors and potential ITIS
cut-off points within a non-parametric fashion,48 and (2) ﬁtted
interactions between the ITIS, tumor stage and adjuvant che-
motherapy to gauge potential effect modiﬁcation. The code for
all analyses is available on request from FP.
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Supplemental Tables 
 
Supplemental Table 1. TLS density by selected clinical covariables 
 
Variable Median TLS 
density 
[25th-75th 
percentile] 
p for 
difference 
Spearman’s 
Rho / p value 
Tumor grade G1+G2 
(n=58) 
0.47 [0.24-0.84] 0.720 
 
N/A 
Tumor grade G3 (n=51) 0.53 [0.18-0.90] N/A 
UICC Stage II (n=41) 0.44 [0.24-0.84] 0.900 
 
N/A 
UICC Stage III (n=68) 0.50 [0.23-0.87] N/A 
ECOG PS: 0 points (n=72) 0.50 [0.22-0.84] 0.813 
 
N/A 
ECOG PS: ≥ 1 point (n=34) 0.47 [0.21-0.90] N/A 
Age < 75 years (n=83) 0.50 [0.24-0.88] 0.434 
 
N/A 
Age ≥ 75 years (n=26) 0.42 [0.18-0.69] N/A 
MSI-H (n=10) 0.69 [0.52-1.04] 0.063 N/A 
Not MSI-H (n=98) 0.45 [0.21-0.84] N/A 
BRAF mut (n=10) 0.61 [0.52-1.12] 0.038 N/A 
MSS/BRAF wt (n=97) 0.44 [0.18-0.84] N/A 
ALC < Q3 (n=77) 0.44 [0.18-0.77] 0.009 0.27 / 0.006 
ALC ≥ Q3 (n=28) 0.75 [0.34-1.39] 
NLR< Q3 (n=78) 0.52 [0.25-0.95] 0.040 -0.26 / 0.007 
 NLR ≥ Q3 (n=27) 0.39 [0.17-0.64] 
Abbreviations: N/A – not applicable, UICC – Union international pour le lutte contre 
le cancer, ECOG PS – Eastern Cooperative Oncology Group performance status, 
MSI-H – highly instable microsatellite status (by immunohistochemistry), MSS – 
stable microsatellite status (by immunohistochemistry), ALC – absolute lymphocyte 
count, Q3 – 3rd quartile (i.e. 75th percentile of the variable’s distribution), NLR – 
neutrophil/lymphocyte ratio. 
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Supplemental Table 2. Multivariable competing risk regression models of 3-year 
recurrence risk with TLS parameters and clinical covariables with further 
adjustment for MSI-H and BRAF mutation status  
 
Model Variable SHR 95%CI p 
     
Multivariable 
Model #S1 
TLS/mm ≤ Q1 3.82 1.21-12.04 0.022 
Age ≥ 75 years 5.66 1.69-18.91 0.005 
ECOG performance status > 
0 
7.99 2.64-24.12 <0.0001 
UICC tumor stage III 2.33 0.78-6.99 0.132 
Adjuvant chemotherapy 2.10 0.58-7.53 0.257 
MSI-H or BRAFmut 0.69 0.20-2.42 0.560 
     
Multivariable 
Model #S2 
% E-TLS ≥ Q3 3.75 1.20-11.71 0.023 
Age ≥ 75 years 4.98 1.86-13.30 0.001 
ECOG performance status > 
0 
7.31 2.09-25.54 0.002 
UICC tumor stage III 1.91 0.50-7.27 0.343 
Adjuvant chemotherapy 1.23 0.33-4.65 0.757 
MSI-H or BRAFmut 0.73 0.20-2.67 0.636 
     
Multivariable 
Model #S3 
% PFL-TLS ≤ Q1 4.02 1.28-12.59 0.017 
Age ≥ 75 years 4.09 1.16-14.42 0.029 
ECOG performance status > 
0 
6.84 1.60-29.18 0.009 
UICC tumor stage III 2.18 0.59-8.02 0.239 
Adjuvant chemotherapy 1.80 0.49-6.64 0.375 
MSI-H or BRAFmut 0.76 0.19-3.06 0.704 
     
Multivariable 
Model #S4 
% SFL-TLS ≤ Q1 3.96 1.09-14.41 0.037 
Age ≥ 75 years 4.89 1.72-13.88 0.003 
ECOG performance status > 
0 
5.77 1.85-17.96 0.002 
UICC tumor stage III 3.49 0.94-12.90 0.061 
Adjuvant chemotherapy 0.92 0.30-2.84 0.889 
MSI-H or BRAFmut 0.98 0.23-4.06 0.973 
Results were estimated with multivariable Fine & Gray competing risk regression 
models, treating death-from-any-cause as the competing event of interest. 
Abbreviations: SHR – Subdistribution hazard ratio, 95%CI – 95% confidence 
interval, TLS/mm – TLS count, ECOG – Eastern Cooperative Oncology Group, 
UICC – Union Internationale pour le lutte contre le cancer, MSI-H – Highly instable 
microsatellite status, BRAFmut – BRAF V600E mutation, % E-TLS – Proportion of 
Early tertiary lymphoid structure (TLS), Q1 – 25th percentile of the variable’s 
distribution (i.e. quartile 1 (Q1)), % PFL-TLS – Proportion of primary follicle-like 
TLS, % SFL-TLS – Proportion of secondary follicle-like TLS. 
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Supplemental Table 3. Path coefficients and intercepts of the structural equation 
model summarizing TLS parameters for predicting 3-year time-to-recurrence 
  
Path 
(Measurement <- latent variable) 
Path coefficient 
(95%CI) 
Intercept 
(95%CI) 
   
TLS/mm <- immune_context 0.11 (0.03-0.20) 0.63 (0.52-0.74) 
E-TLS <- immune_context -18.68 (-20.53-(-
16.84)) 
56.12 (51.94-60.29) 
PFL-TLS <- immune_context 9.76 (6.90-12.62) 24.33 (20.72-27.93) 
SFL-TLS <- immune_context 8.92 (6.41-11.43) 19.56 (16.16-22.96) 
time2mets <- immune_context -0.54 (-0.96-(-0.11)) -2.90 (-3.62-(-2.17)) 
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Supplemental Table 4. Reagents used for the assessment of TLS in CRC tissues  
 
Primary 
antibodies (clone) 
Antigen 
retrieval 
buffer 
Incubation 
time, 
minutes 
Secondary 
antibody (name, 
conjugate) 
Detection 
CXCL13 
(polyclonal, R&D 
Systems) 
CC1 32 32 Anti-Goat IgG-HRP TSA-
FITC 
CD23 (1B12) CC1 24 32 Anti-Mouse IgG-
HRP 
TSA-Cy5 
CD21 (2G9)  CC1 24 32 Anti-Mouse IgG-
HRP 
TSA-Cy3 
CD3 (SP7) Trilogy overnight Anti-Rabbit IgG AF-594 
CD20 (L26) Trilogy overnight Directly labelled eFluor660 
CCL21 (polyclonal, 
R&D Systems) 
Trilogy overnight Anti-Goat IgG-HRP TSA-
FITC 
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Supplemental Table 5. Primers used for BRAF V600E mutation status 
assessment  
 
 BRAF V600E reverse primer CCCACTCCATCGAGATTTCT 
  Reference reverse 
Primer 
CAACTGTTCAAACTGATGGG 
  Forward Primer CTGTTTTCCTTTACTTACTACACCTCAGAT 
  Probe FAM-CACAGTAAAAATAGGTGAT-MGB 
Internal 
control 
Forward Primer CCCTAGAGTTGCCACAGC 
  Reverse Primer GGTAAGCAGCAAGAGAGC 
  Probe VIC-CTGTCTATCTTGCCTGCC-MGB 
Probe for BRAF were labelled with 6-fluorescein (FAM) at 5’end and a minor 
grove binding domain (MGB) at 3’end. TaqMan probe for internal control PCR 
detection was labelled with VIC-fluorophore at 5’end and a MGB at 3’end.  
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Supplemental Figures 
 
 
Supplemental Figure 1. Cumulative 3-year risk of recurrence in the overall study 
population 
Risk was estimated with competing risk cumulative incidence estimators, treating 
death-from-any-cause as the competing event of interest. 
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Supplemental Figure 2. Predicted rate of recurrence at different times of follow-
up 
The recurrence rate was estimated with a flexible parametric model on the 
log(cumulative hazard scale) with 3 degrees of freedom. 
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Supplemental Figure 3. TLS development in CRC with various genetic 
alterations 
The density of total TLS and TLS in each maturation stage was assessed by 
multiparameter IF staining and compared for patients with microsatellite stable wild 
type BRAF tumors (MSS, n=94) versus patients with (A) MSI-H status (n=10) or (B) 
mutated BRAF (n=10) by a Wilcoxon rank-sum test.   
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Supplemental Figure 4. Histogram of the Integrated TLS ImmunoScore (ITIS) 
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Supplemental Figure 5. Scatter plot of the Integrated TLS ImmunoScore (ITIS) 
and the Empirical Bayes predictions of the latent “immune_context” variable 
from the structural equation model 
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Supplemental Figure 6. Classification and regression tree analysis (CART) of 3-
year recurrence risk in non-metastatic CRC 
Five variables were considered for CART, namely the ITIS (“itis”), age ≥ 75 years 
(“age”), UICC tumor stage II vs. III (“stage3”), ECOG performance status > 0 points 
(“ecognotzero”), and adjuvant chemotherapy (“adjchemo”). Split was performed with 
a threshold for split at p<0.05. ECOG performance status and the ITIS were selected 
by the CART as the two strongest determinants of recurrence risk. CART analysis 
yielded a cut-off at -12 points to separate low ITIS (-33 – -12), and high ITIS (-11 – 
43). Abbreviations: RHR – Relative hazard ratio.!
 N  F  RHR
 ecognotzero
 0  69  5  .38
 -11-43  24  6  1.55
 1  itis
 -33--12  10  7  7.10
 CART analysis  - Split if (adjusted) P<.05
 With variables: itis age75 stage ecognotzero adjchemo
